CD Protein Inhibitors News

«1 2...33 34 35 36 373839 40 41 42 43...3931 3932 »

|||||||||| Rituxan (rituximab) / Roche
CHYLOTHORAX AS A RARE PULMONARY COMPLICATION OF NEWLY DIAGNOSED WALDENSTROM MACROGLOBULINEMIA (Convention Center Exhibit Hall: Rapid Fire Area 3D) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6484;
Presentation of chylothorax should raise suspicion for malignancy on a patient's differential. Thorough and timely workup is important for further management including medical therapy with chemotherapy, chest tube placement or even pleurodesis if indicated.

|||||||||| Rituxan (rituximab) / Roche
DIFFUSE ALVEOLAR HEMORRHAGE IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA)-ASSOCIATED VASCULITIS: A CASE REPORT WITH PREDOMINANT RIGHT LUNG INVOLVEMENT (Convention Center Exhibit Hall: Poster Area 4) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6443;
Additionally, the predominant involvement of the right lung in this case underscores the variability in disease presentation and warrants further investigation into its underlying mechanisms and prognostic implications. Early recognition and prompt initiation of immunosuppressive therapy are crucial in improving outcomes in patients with AAV complicated by DAH, especially when presenting with uncommon features such as right-sided involvement.

|||||||||| Rituxan (rituximab) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
MICROSCOPIC POLYANGIITIS; A RARE PRESENTATION WITH CARDIAC TAMPONADE AND A COMPLEX PLEURAL EFFUSION (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6440;
Clinicians should be vigilant regarding rare initial presentations of vasculitis especially in the setting of multiorgan involvement. Specific findings of pericarditis or cardiac tamponade with pleural effusions with AKI without resolution should raise a question of vasculitis and should be ruled out in order promptly to start immunosuppressive therapy.

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Imfinzi (durvalumab) / AstraZeneca
THE LAST BREATH: CONFRONTING MORTALITY IN CHECKPOINT INHIBITORS (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6433;
Physicians should be aware of the varied features of checkpoint inhibitor pneumonitis (CIP) and consider the use of immunosuppressive agents when necessary. CIP signifies the role of interdisciplinary collaboration in managing it, and palliative care plays a significant role in providing comfort and support to patients with poor prognosis.

|||||||||| Rituxan (rituximab) / Roche
SCRATCHING THE SURFACE OF A COMPLEX SYNDROME INVOLVING SURFACTANT: PULMONARY ALVEOLAR PROTEINOSIS FOLLOWING DISSEMINATED CRYPTOCOCCAL INFECTION (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6430;
PAP is a disease characterized by anti-GM-CSF autoantibodies resulting in loss of alveolar macrophage function and decreased surfactant catabolism. PAP treatments include GM-CSF supplementation, rituximab, or whole lung lavage.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
CHECK YOURSELF BEFORE YOU WRECK YOURSELF: A CASE OF PEMBROLIZUMAB-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6423;
If recognized early and treated appropriately, the vast majority of patients recover. Unfortunately, patients with multiple comorbidities or poor functional baseline may not do as well or may need additional treatment such as IVIG or biologics such as rituximab.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
BREAKING BOUNDARIES: UNRAVELLING THE ENIGMA OF LARGE CELL NEUROENDOCRINE CANCER (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6420;
LCNEC of the lung is a rare and aggressive malignancy with poor prognosis that resembles SCLC in histological characteristics but has treatment guidelines extrapolated from NSCLC. Given the high frequency of brain metastasis, revision of treatment guidelines to possibly include prophylactic brain irradiation is necessitated and further multi-institutional research studies are required to achieve a deeper insight into its behaviour and management.

|||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
HISTIOCYTIC SARCOMA PRESENTING AS MEDIASTINAL LYMPHADENOPATHY (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6406;
HS is an aggressive and rare hematopoietic malignancy that presents with a variety of symptoms. A high degree of suspicion is required for an accurate and timely diagnosis.

|||||||||| Ocrevus (ocrelizumab) / Roche
A RARE CASE OF ORGANIZING PNEUMONIA DUE TO OCRELIZUMAB (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6402;
al., making this the second case report of ocrelizumab-induced COP. This case raises awareness of potential complications of ocrelizumab requiring close monitoring.

|||||||||| Rituxan (rituximab) / Roche
EFFICIENT SEROLOGIC DIAGNOSIS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY VASCULITIS WITH INTERSTITIAL LUNG DISEASE: A NONINVASIVE APPROACH (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6401;
We are reporting the first known case of 6-year delayed diagnosis of pulmonary fibrosis due to c-ANCA vasculitis, successfully confirmed by serology and without bronchoscopy or open lung biopsy. A high index of suspicion for ANCA in patients that display atypical pneumonia with an interstitial lung disease pattern can lead to early accurate diagnosis and appropriate treatment.

|||||||||| Rituxan (rituximab) / Roche
ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA) VASCULITIS WITH ACUTE INTERSTITIAL NEPHRITIS (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6382;
Treatment with prednisone and rituximab led to improvement in kidney function. This case adds to the evidence supporting the possible occurrence of AAV-associated AIN and highlights the importance of recognizing this presentation for effective management.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
NAVIGATING HYPOPHYSITIS IN THE WAKE OF IMMUNOTHERAPY: A DUAL-AGENT PERSPECTIVE WITH PEMBROLIZUMAB AND IPILIMUMAB: A CASE REPORT (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6371;
The broadening spectrum of immune-related toxicities underscores the need for ongoing research into predictive biomarkers and tailored management strategies. This is crucial for enhancing the safety and efficacy of combination immunotherapies.

|||||||||| Cytovene (ganciclovir) / Roche, Rituxan (rituximab) / Roche
EXPLORING THE CRITICAL INTERSECTION OF HUMAN IMMUNODEFICIENCY VIRUS, HUMAN HERPESVIRUS 8, AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6355;
This case demonstrates the necessity of prompt consideration of KICS and KSHV-MCD in patients with HIV, HHV-8, and SIRS, as patients can rapidly decompensate preventing potential treatment. Continued work is needed to educate physicians on these rare syndromes.

|||||||||| IMMUNE CHECK POINT INHIBITOR USE CAUSING A FULMINANT DKA CASE IN ICU (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6353;
Oncology patients can develop serious adverse effects by immunotherapy; in the form checkpoint inhibitor associated type 1diabetes with its life threatening complication in a patient with no prior history of diabetes. Education of the patients and close monitoring for hyperglycemia and further endocrine workup should be done by primary care physicians and specialists for early diagnosis and supportive care of the patients on ICIs.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
A BROKEN HEART: A CASE OF IPILIMUMAB AND NIVOLUMAB-INDUCED MYOCARDITIS (Convention Center Exhibit Hall: Poster Area 1) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6317;
Immune checkpoint inhibitors may cause several immune-related side effects; one rare side effect is cardiac toxicity, including myocarditis. Though these side effects are rare, they have a high mortality rate; As a result a high index of suspicion is imperative for early diagnosis and treatment of these cohorts of patients.

|||||||||| Opdivo (nivolumab) / BMS
ARE IMMUNE-RELATED TOXICITIES GOOD NEWS IN DISGUISE? A RARE OCCURRENCE OF NIVOLUMAB-INDUCED PERICARDIAL EFFUSION IN METASTATIC ESOPHAGEAL CANCER (Convention Center Exhibit Hall: Poster Area 1) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6315;
Our patient also had a favorable outcome in terms of his cancer status after nivolumab-induced pericardial effusion. Nevertheless, further research is essential to refine our understanding of irAEs, as they may not always correlate with unfavorable cancer outcomes.

|||||||||| Ocrevus (ocrelizumab) / Roche
A RARE CASE OF ORGANIZING PNEUMONIA INDUCED BY OCRELIZUMAB (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6096;
Ocrelizumab is a very rare cause of OP. A thorough history and broad differential need to be considered for appropriate diagnosis of OP as removal of the offending agent is indicated.

|||||||||| Darzalex (daratumumab) / J&J
DARATUMUMAB-INDUCED SUBACUTE FIBRINOUS ORGANIZING PNEUMONIA (Convention Center Exhibit Hall: Poster Area 3) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6039;
Daratumumab is an antineoplastic agent that can potentially cause AFOP, a rare type of interstitial pneumonia. In patients with interstitial pneumonia and negative infectious workup, lung biopsy, and histopathology can help diagnose AFOP and differentiate from other mimics such as lung malignancy and fungal pneumonia.

|||||||||| Nulojix (belatacept) / BMS
DISSEMINATED HISTOPLASMOSIS IN A PATIENT WITH ACUTE KIDNEY TRANSPLANT REJECTION: A CASE REPORT OF DARLING'S DISEASE (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6031;
Our study, while illustrating many signs of this rare disease, begs the question of whether there is a specific association between kidney transplants and histoplasmosis. Furthermore, the relationship between acute transplant rejection and a temporal association between the first 1-2 years of transplant and development of histoplasmosis is yet to be clearly identified.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
IMMUNOTHERAPY-INDUCED DIABETIC KETOACIDOSIS (Convention Center 256) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6023;
All patients who are started on ICI's should be educated on signs and symptoms of DKA and the need to seek urgent medical attention if symptoms arise. For patients with pre-existing diabetes, insulin therapy for be initiated immediately.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
ACHIEVING REMISSION IN METASTATIC SARCOMATOID LUNG CARCINOMA WITH PEMBROLIZUMAB AND PLATINUM-DOUBLET TREATMENT (Convention Center Exhibit Hall: Rapid Fire Area 3D) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5959;
This case underscores the critical role of advanced molecular diagnostics in guiding the management of complex cancer cases. The successful application of Pembrolizumab in a patient with Sarcomatoid carcinoma, characterized by a high PDL-1 expression, adds valuable insight into the potential of immunotherapy in treating rare and aggressive forms of cancer.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
MYOPATHY LEADING TO RHABDOMYOLYSIS AS A RARE SIDE EFFECT OF LENVATINIB AND PEMBROLUZIMAB THERAPY (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5900;
Myositis and rhabdomyolysis have also been reported in the literature as a rare side effect in anti-PDL-1 drugs, such as pembrolizumab, and anti-CTLA-4 drugs, such as ipilimumab.[3,4] One proposed mechanism to this process is new autoimmune hypothyroidism leading to rhabdomyolysis.[5] In patients who are on both TKI's and ICI's, it may be difficult to discern the instigating agent as illustrated in this case report...Prior to admission, she was taking amlodipine, diazepam, glipizide, Lantus, levothyroxine, lisinopril-hydrochlorothiazide, metformin, rosuvastatin, pembrolizumab, and lenvatinib for several months... Serial CK levels can be useful in patients presenting to the clinic with muscle pain or weakness.7 Routine screening for musculoskeletal symptoms in patients on TKI's and ICI's should be a part of regular follow up.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Journal: Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapy. (Pubmed Central) - Sep 10, 2024
While pembrolizumab showed no change in charge variants post-PIPAC, trastuzumab-deruxtecan exhibited a non-negligible change in the quantity of charge variants on the monoclonal antibody itself, while the payload remained unchanged. This shift could possibly be related to the metallic composition of the CapnoPen

|||||||||| Tyvyt (sintilimab) / Eli Lilly
Clinical, Journal, Metastases: Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. (Pubmed Central) - Sep 10, 2024
P2
Adding the PD-1 antibody sintilimab to NACRT significantly increases the CR rate in pMMR LARC, with a manageable safety profile. PD-L1 positivity may help identify patients who might benefit most from the combination therapy.

|||||||||| Imfinzi (durvalumab) / AstraZeneca, Tagrisso (osimertinib) / AstraZeneca
Hypothetical Self-Treatment Preferences for Locally Advanced NSCLC Differ by Physician Specialty: Is the Best Option in the Eye of the Beholder? (Sheraton Times Square, Empire West) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_100;
Surgeons tended to favor resection and place greater emphasis on surgery over radiation as a form of local therapy. The reasons for these patterns are unclear and may be due to differing levels of comfort with specific treatment paradigms, personality differences inherent to each specialty, or other differences between the groups.

|||||||||| Tecentriq (atezolizumab) / Roche
Five-Year Follow-Up of IMpower010: Exploratory Analysis of Outcomes and Safety by Extent of Resection in Stage II-IIIA Non-Small Cell Lung Cancer (NSCLC) (Sheraton Times Square, Empire East) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_93;
P3
After ?5 years of follow-up in IMpower010, patients who underwent lobectomy and received adjuvant atezolizumab after chemotherapy had greater DFS and OS improvements than those who received BSC after adjuvant chemotherapy in the prespecified PD-L1 TC ?1% and ?50% populations, although patient numbers were limited across surgery types, particularly for bilobectomy. The AE profiles of patients who underwent pneumonectomy/bilobectomy and lobectomy/sleeve lobectomy were similar between surgical subgroups after adjuvant chemotherapy and atezolizumab.

|||||||||| Tecentriq (atezolizumab) / Roche
LCMC3: survival impact of circulating tumor (ct)DNA status after neoadjuvant atezolizumab (atezo) on radiographic and pathologic response, resection status, and adjuvant (adj) atezo treatment in NSCLC (Sheraton Times Square, Metropolitan East) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_65;
P2
Similarly, post-surgery ctDNA clearance was more prognostic of DFS and OS than post-atezo ctDNA clearance and any ctDNA status, although status does not require longitudinal sampling. The survival trends for R0 vs R0(un) suggest that some pts may be understaged due to inadequate lymph node dissection.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Pathological complete response to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel plus or minus durvalumab in resectable gastric and gastroesophageal junction cancer: MATTERHORN subgroup results (Sheraton Times Square, Empire East) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_58;
P3
Conclusions In MATTERHORN, pCR was consistently improved with the addition of D to perioperative FLOT in GC/GEJC across geographic regions. The study is ongoing for the primary objective of event-free survival.

|||||||||| Opdivo (nivolumab) / BMS
Surgical Outcomes With Perioperative Nivolumab in Patients With Resectable Non-Small Cell Lung Cancer From the Phase 3 CheckMate 77T Study (Sheraton Times Square, Central Park) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_54;

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
TISLELIZUMAB PLUS CHEMOTHERAPY SEQUENTIAL NEO-CHEMORADIOTHERAPY THERAPY AS TOTAL NEOADJUVANT THERAPY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA(ETNT) (Sheraton Times Square, Central Park) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_43;
P2
Survival analysis is ongoing. CONCLUSIONS This study explored the safety and efficacy of tislelizumab plus neo-chemoradiotherapy for treating locally advanced ESCC, offering a promising total neoadjuvant therapy approach.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Pericardial Mesothelioma: Is there a Role for Surgery in the Age of Immunotherapy? A Case Report and Review of Literature (Sheraton Times Square, Central Park) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_25;
As with pleural mesothelioma, the standard of care treatment is systemic therapy, and the role of surgery remains controversial. In this case, with the patient in imminent cardiovascular collapse electing the aggressive option, her life was clearly extended, and she was able to return home and resume standard of care immunotherapy.

|||||||||| Verzenio (abemaciclib) / Eli Lilly
Mapping microRNA Functions in Mesothelioma can Lead to Novel Precision Therapies (Sheraton Times Square, Central Park) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_22;
Our discovery platform systematically integrates new, customized bioinformatic algorithms with experimental testing (in vitro and in vivo) to efficiently sort therapeutic miRNAs and identify DPM-related genes, some of which are novel. We are establishing a new treatment paradigm and combinatorial library of miR+drug that expands the DPM thera

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant Pembrolizumab (pembro) or Placebo (pbo) Plus Chemotherapy and Adjuvant Pembro or Pbo for Early-Stage NSCLC: Subgroup Analyses of the Phase 3 KEYNOTE-671 Study (Sheraton Times Square, Metropolitan East) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_7;

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Perioperative durvalumab for resectable (R) NSCLC: updated analyses from the phase 3 AEGEAN trial (Sheraton Times Square, Metropolitan East) - Sep 10, 2024 - Abstract #AATSITSOS2024AATS_ITSOS_6;

||||||||||  Rituxan (rituximab) / Roche
New P4 trial:  Evaluation of the particular characteristics of patients with kidney diseases that could affect the behavior of rituximab in their organism. Investigaci (EUDRACT) -  Sep 10, 2024
P4, N=35, Ongoing,  Sponsor: Vall d'Hebron Institute of Research

|||||||||| Xalkori (crizotinib) / Pfizer, Cabometyx (cabozantinib tablet) / Exelixis, Orpathys (savolitinib) / AstraZeneca, Hutchmed
P2 data, Journal, Metastases: Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. (Pubmed Central) - Sep 10, 2024
P2
In conclusion, we observed no significant difference in OS across treatment arms. Although cabozantinib represents a well-supported option for advanced PRCC, the lack of survival benefit underscores the need to develop novel therapies for this disease.

|||||||||| Opdivo (nivolumab) / BMS
Journal: Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma. (Pubmed Central) - Sep 10, 2024
Here, we leverage genome-wide CRISPR/Cas9 screens and identify H2AFY as a resistance gene to the clinically approved PD-1 blocking antibody, nivolumab...With a multi-omics approach, we uncover H2AFY-associated genes that are functionally relevant and prognostic in patients. Altogether, our study elucidates the role of H2AFY as an epigenetic gatekeeper for cell states and immunogenicity in high-risk neuroblastoma.

|||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Keytruda (pembrolizumab) / Merck (MSD)
Journal, Tumor mutational burden, PD(L)-1 Biomarker: Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden. (Pubmed Central) - Sep 10, 2024
Altogether, our study elucidates the role of H2AFY as an epigenetic gatekeeper for cell states and immunogenicity in high-risk neuroblastoma. To our knowledge, this is the first report showing the efficacy of pembrolizumab in a patient with cholangiocarcinoma harboring both HER2-positive and TMB-H.

|||||||||| Tavneos (avacopan) / Amgen
Journal, Combination therapy: Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report. (Pubmed Central) - Sep 10, 2024
Temporary hemodialysis was required, and the patient successfully discontinued dialysis after 12 sessions despite a poor histological prognosis. This case underscores the significance of considering aggressive therapeutic strategies, including avacopan, for severe anti-GBM nephritis, even in the absence of lung involvement, to avert the need for KRT.

|||||||||| Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Review, Journal: Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) - Sep 10, 2024
The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.

|||||||||| Rituxan (rituximab) / Roche
Journal: Secondary hypogammaglobulinemia: diagnosis and management of a pediatric condition of clinical importance. (Pubmed Central) - Sep 10, 2024
The clinical relevance of SHG in pediatrics is increasingly appreciated. Improved understanding of the specific etiologies, risk factors, and natural history of SHG have informed screening and management recommendations.

|||||||||| Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Journal: Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) - Sep 10, 2024
The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.

|||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Review, Journal: QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 10, 2024
Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.

|||||||||| Tecentriq (atezolizumab) / Roche
Journal: Facile Rebridging Conjugation Approach to Attain Monoclonal Antibody-Targeted Nanoparticles with Enhanced Antigen Binding and Payload Delivery. (Pubmed Central) - Sep 10, 2024
They showed significant enhancements compared to free paclitaxel and NP-NHS Ab. Overall, this work will provide a facile conjugation method that could be implemented to actively target NPs with a plethora of therapeutic mAbs approved for various malignancies.

|||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Retrospective data, Review, Journal, Immunomodulating: Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. (Pubmed Central) - Sep 10, 2024
Given the relative rarity of PMS, controlled, non-randomised studies on large samples may usefully integrate data from pivotal RCTs. Outcomes valuable and meaningful to people with PMS should be consistently adopted and measured to permit the evaluation of relative effectiveness among treatments.

|||||||||| Rituxan (rituximab) / Roche
Review, Journal: An unusual case of early onset opsoclonus-myoclonus syndrome: Case report and literature review. (Pubmed Central) - Sep 10, 2024
Despite the range of therapeutic options for managing opsoclonus-myoclonus syndrome described in the literature, the efficacy of these available therapies needs to be better established. A modified upfront approach with dexamethasone and intravenous immunoglobulin could be an option in settings where rituximab is unavailable.

|||||||||| Journal: Mechanistic modeling of cell viability assays with in silico lineage tracing. (Pubmed Central) - Sep 10, 2024
Variations in mother cells prior to drug treatment all impinging on ERK pathway activity are associated with the rapidly dividing phenotype and trametinib resistance. This work lays a foundation for the application of mechanistic modeling to large-scale cell viability assay datasets and better understanding determinants of cellular heterogeneity in drug response.

|||||||||| Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Journal: Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition. (Pubmed Central) - Sep 10, 2024
Basic research indicates that JAK1 plays a role in the cytokine signal transduction in ILD; however, there are no clinical reports on the efficacy of filgotinib in RA-ILD. This case suggests filgotinib as a potential treatment for patients with RA-ILD, particularly in the early stages of this disease.

|||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: An exploratory clinical study of ?-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma. (Pubmed Central) - Sep 10, 2024
Advanced gastric adenocarcinoma patients received ?-glucan, camrelizumab, oxaliplatin, oral S-1 every 3 weeks...This preliminary study demonstrates that ?-glucan plus camrelizumab and SOX chemotherapy offers favorable efficacy and a manageable safety profile in patients with advanced gastric adenocarcinoma, and further studies are needed to verify its efficacy and safety. Chinese Clinical Trials Registry, identifier ChiCTR2100044088.

|||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Review, Journal: Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review. (Pubmed Central) - Sep 10, 2024
Despite the encouraging clinical potential of LAG-3, the physiological function and mechanism of action in tumors are still not well understood. In this review, we systematically summarized the structure of LAG-3, ligands of LAG-3, cell-specific functions and signaling of LAG-3, and the current status of LAG-3 inhibitors under development.



	Diseases Companies Products Productz Mechanisms of Action Sites